SGLT2 Inhibitors
Sort by:
Symposium on Diabetes and Cancer 2017: Novel Links and Treatments
Primer on Diabetes Management
FEATURING
Silvio Inzucchi
- 39,891 views
- June 16, 2017
- 195
Cardiology Fiesta 2017
Renal, Metabolic and Cardiovascular Considerations of SGLT2 Inhibition
FEATURING
Ralph DeFronzo
- 9,424 views
- November 10, 2017
- 64
ACC 2022 Conference Coverage
ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendations for HFrEF and HFmrEF Treatment
FEATURING
Paul Heidenreich
- 18,898 views
- April 21, 2022
- 59
ACC 2023 Conference Coverage
ACC 2023: Failure to Treat With Pharmacologic GDMT After an MI: Opportunities Lost
FEATURING
Vicki Groo
- 1,345 views
- April 3, 2023
- 4
ASPC 2019 Congress on CVD Prevention
Diabetes Treatment Guidelines Finally Have Entered the 21st Century - Almost
FEATURING
Ralph DeFronzo
- 11,582 views
- August 12, 2019
- 58
ACC 2023 Conference Coverage
ACC 2023: SGLT2i Use - Dos and Don'ts
FEATURING
Anastasia Armbruster
- 17,429 views
- March 31, 2023
- 95
Emory Diabetes Education Training Academy
Insulin Treatment in Patients with Type 2 Diabetes: When to Use Combination Therapy
FEATURING
Guillermo Umpierrez
- 3,780 views
- May 15, 2020
- 22
American Heart & Vascular Institute
Cardiorenal Syndrome From the Nephrologist Perspective: Chicken or the Egg
FEATURING
Swapnil Hiremath,
Sohail Khan
- 762 views
- September 16, 2021
- 5
Cardiometabolic Health Congress (CMHC)
COVID-19 & Obesity: Is There any Evidence that Obese Patients Have a Higher Risk of Infection? Could Obesity Be a Factor in the Death Toll in the Younger Population? Should SGLT2 Inhibitors and Other Therapies Be Discontinued Upon Hospitalization?
FEATURING
Robert Eckel
- 1,285 views
- May 22, 2020
- 10
13th Orange County Symposium for Cardiovascular Disease Prevention
SGLT2 inhibitors and GLP-1 agonists: Why Are They Important and Which Do I Choose?
FEATURING
Yehuda Handelsman
- 3,406 views
- January 27, 2022
- 15
Primary Care Education Consortium
A Pathophysiologic Approach for Treating Type 2 Diabetes: Part 2
FEATURING
Eden Miller
- 2,358 views
- November 30, 2023
- 20
Cardiometabolic Health Congress (CMHC)
SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes
FEATURING
Lance Sloan
- 7,999 views
- June 17, 2019
- 48
ACC 2022 Conference Coverage
Hot Topics in Heart Failure ACC.22
FEATURING
Nasrien Ibrahim
- 3,493 views
- April 22, 2022
- 33
Cardiometabolic Health Congress (CMHC)
Updated Type 2 Diabetes Guidelines
FEATURING
Wendy Lane
- 727 views
- May 7, 2018
Mount Sinai Advanced Innovations in Heart Failure
Medical Therapy for Heart Failure in 2022
FEATURING
Anuradha Lala-Trindade
- 1,021 views
- March 2, 2022
- 11
ACC 2023 Conference Coverage
ACC 2023: Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF - An Invasive Hemodynamic Randomized Trial
FEATURING
Barry Borlaug
- 1,317 views
- March 15, 2023
- 9
Naveed Sattar
Can Empagliflozin Successfully Treat T2D Whilst Preventing Heart Failure and Protecting Renal Function?
- 819 views
- November 25, 2020
- 3
Christos Argyropoulos
Diabetic Kidney Disease Treatment: When to Use SGLT2 Inhibitors & Who Should Prescribe Them?
- 1,256 views
- December 14, 2020
- 3
George Bakris
Current Status of Prevention and Treatment of Diabetic Nephropathy
- 3,363 views
- August 20, 2018
- 24
John Tayek
2020 Updates on Insulin Therapy: What Are the Current ADA Standards of Care?
- 2,466 views
- November 25, 2020
- 13